Cover Image

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series

ObjectivesAttenuated humoral response to mRNA SARS-CoV-2 vaccines has been reported in some patients with autoimmune disease, e.g., rheumatoid arthritis (RA). However, data of immune responses to inactivated SARS-CoV-2 vaccine in the RA population are still unknown. Herein, the safety and immunogeni...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ting Zhao (Author), Jiayan Shen (Author), Youyang Zhu (Author), Xiaofang Tian (Author), Guangfen Wen (Author), Yuanyuan Wei (Author), Bonan Xu (Author), Chenyang Fu (Author), Zhaohu Xie (Author), Yujiang Xi (Author), Zhenmin Li (Author), Jiangyun Peng (Author), Yang Wu (Author), Xiaohu Tang (Author), Chunping Wan (Author), Lei Pan (Author), Zhaofu Li (Author), Dongdong Qin (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
by: Yan Zhou, et al.
Published: (2023)

Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice
by: Aqian Li, et al.
Published: (2022)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
by: Juan Li, et al.
Published: (2021)

LncRNA ZNF667-AS1 alleviates rheumatoid arthritis by sponging miR-523-3p and inactivating the JAK/STAT signalling pathway
by: Qin Zhuo, et al.
Published: (2021)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
by: Shuyu Gao, et al.
Published: (2022)

Fucoidan alleviates the hepatorenal syndrome through inhibition organic solute transporter α/β to reduce bile acids reabsorption
by: Xiaojuan Zhao, et al.
Published: (2023)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
by: Ainur Nurpeisova, et al.
Published: (2022)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

How to Increase the Immunogenicity of SARS-COV-2 Inactivated Vaccines?
by: Yousef Khadivi
Published: (2021)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine.
by: Shi-Hsia Hwa, et al.
Published: (2013)

Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis
by: Yu Liang, et al.
Published: (2021)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
by: Lairun Jin, et al.
Published: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
by: Zhaojun Mo, et al.
Published: (2017)

Effect of aging on immunogenicity and efficacy of inactivated influenza vaccines in cotton rats Sigmodon hispidus
by: Marina S. Boukhvalova, et al.
Published: (2021)

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China
by: Shi-Yuan Wang, et al.
Published: (2017)

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
by: Xiaoyuan Huang, et al.
Published: (2022)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
by: Cecilia Montalban, et al.
Published: (2018)

Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants
by: Shelina Moonsamy, et al.
Published: (2019)

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis
by: Sandrine I. Samson, et al.
Published: (2019)

A phase Ⅱ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine
by: Rong Tang, et al.
Published: (2020)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
by: Rui Hu, et al.
Published: (2023)

Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis
by: Guihua Tang, et al.
Published: (2018)

Immunogenicity and safety of inactivated Influenza Split-Virion vaccine administered via a Transdermal Microneedle System
by: Mahmoud Ameri, et al.
Published: (2021)

Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
by: Pornthep Chanthavanich, et al.
Published: (2018)

Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines
by: Allegra Peletta, et al.
Published: (2024)

Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.
by: Yi-Chin Fan, et al.
Published: (2015)

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
by: Jianmin Chen, et al.
Published: (2023)

Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study
by: Qiao Guo, et al.
Published: (2022)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
by: Michael Kwan Leung Yu, et al.
Published: (2023)

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
by: Huiqiong Zeng, et al.
Published: (2022)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
by: Timo Vesikari, et al.
Published: (2020)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
by: Sharad Agarkhedkar, et al.
Published: (2019)

Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
by: Yajun Shu, et al.
Published: (2024)

Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives
by: Jiayan Huang, et al.
Published: (2024)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
by: Yongliang Feng, et al.
Published: (2021)

Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial
by: Yan Li, et al.
Published: (2021)

Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
by: Pengfei Jin, et al.
Published: (2024)

Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial
by: Yamin Wang, et al.
Published: (2021)